KAI Pharmaceuticals, Inc. Announces Promising Results of KAI-4169 Program for the Treatment of Chronic Kidney Disease-Mineral and Bone Disorder
Published: Jun 07, 2011
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced clinical and preclinical data from its lead program, KAI-4169, at the Endocrine Society's 93rd Annual Meeting (ENDO 2011) taking place in Boston, June 4-7, 2011. KAI-4169 is a novel pharmaceutical agent being developed for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).